DELLA CORTE, Carminia Maria
 Distribuzione geografica
Continente #
EU - Europa 527
NA - Nord America 499
AS - Asia 81
AF - Africa 2
OC - Oceania 1
SA - Sud America 1
Totale 1111
Nazione #
US - Stati Uniti d'America 479
IT - Italia 207
GB - Regno Unito 88
FR - Francia 83
UA - Ucraina 63
CN - Cina 39
GR - Grecia 28
DE - Germania 21
CA - Canada 20
VN - Vietnam 18
FI - Finlandia 12
SE - Svezia 12
TR - Turchia 10
IE - Irlanda 8
JP - Giappone 6
PK - Pakistan 4
BE - Belgio 2
HU - Ungheria 2
IL - Israele 2
AU - Australia 1
CL - Cile 1
IQ - Iraq 1
MA - Marocco 1
PL - Polonia 1
PS - Palestinian Territory 1
SC - Seychelles 1
Totale 1111
Città #
Jacksonville 120
Princeton 66
Roxbury 65
Chandler 39
Cambridge 34
Medford 32
Caserta 29
Wilmington 22
Dong Ket 18
Beijing 17
Elora 17
Ann Arbor 15
Des Moines 14
Napoli 14
Naples 8
San Mateo 6
Woodbridge 6
Jinan 4
Nanjing 4
Norwalk 4
Shanghai 4
Acerra 3
Ercolano 3
Fairfield 3
Houston 3
Mountain View 3
Rome 3
Scafati 3
Toronto 3
Andover 2
Avellino 2
Aversa 2
Bat Hefer 2
Brussels 2
Cinquevie 2
Hanover 2
Helsinki 2
L'aquila 2
Lustra 2
Menlo Park 2
Nanchang 2
Pozzuoli 2
Strasbourg 2
Zhengzhou 2
Antea 1
Ashburn 1
Bari 1
Bedizzole 1
Benevento 1
Bezons 1
Casalnuovo di Napoli 1
Cava De' Tirreni 1
Cervo 1
Changsha 1
Düsseldorf 1
Genova 1
Guangzhou 1
Guido 1
Gunzenhausen 1
Heidelberg 1
Lviv 1
Mahé 1
Mantova 1
Marcianise 1
Marco 1
Marigliano 1
Milan 1
Ningbo 1
Nola 1
Orange 1
Ragusa 1
Ramallah 1
Redmond 1
Redwood City 1
San Marco Evangelista 1
Shenyang 1
Somma Vesuviana 1
Sortino 1
Swansea 1
Taiyuan 1
Tianjin 1
Torino 1
Trumbull 1
Venice 1
Walnut 1
Zagarolo 1
Totale 634
Nome #
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 59
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 45
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 41
Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. 39
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 37
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs 36
Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma 36
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 34
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 34
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 33
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 33
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 32
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 31
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer 30
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 30
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 30
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines 29
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 29
Mechanisms of resistance to EGFR-targeted drugs: lung cancer 28
Primary pleural squamous cell carcinoma: A diagnostic challenge 27
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 27
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. 26
Role and targeting of anaplastic lymphoma kinase in cancer 24
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 24
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy 22
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 22
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 21
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy 20
Implication of the Hedgehog pathway in hepatocellular carcinoma. 19
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 19
Kisspeptin and cancer: Molecular interaction, biological functions, and future perspectives 19
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 18
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 17
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer 16
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 16
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy 14
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 14
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 14
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists 13
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 12
The role of coronary artery calcification score in lung cancer patients 12
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 11
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 11
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 10
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 10
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 9
Role of HGF-MET signaling in primary and acquired resistance to targeted therapies in cancer 8
Hypothalamic–pituitary autoimmunity in patients treated with anti-pd-1 and anti-pd-l1 antibodies 8
Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond 8
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 8
ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer 7
Early use of steroids affects immune cells and impairs immunotherapy efficacy 7
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 7
Immunotherapy for head and neck cancer: Present and future 7
Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors 6
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era 6
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC 6
Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA 5
AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors 5
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype 5
Evading the STING: LKB1 loss leads to STING silencing and immune escape in KRAS-mutant lung cancers 5
Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy 5
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities 4
Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer 4
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology 4
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 4
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign 2
Totale 1254
Categoria #
all - tutte 2563
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2563


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201858 00015 80 19 86110
2018/2019106 1614 339 260 102113
2019/2020236 42301314 255 4319 1813122
2020/2021200 87144 186 3718 15163423
2021/2022463 98129 1016 4516 193162145
2022/2023155 10529210 00 00 0000
Totale 1254